BR9508021A - Composição farmacêutica para o tratamento de distúrbios esquizofrênicos, uso de um agente imunossupressor, e, processo de tratamento de um paciente esquizofrênico - Google Patents

Composição farmacêutica para o tratamento de distúrbios esquizofrênicos, uso de um agente imunossupressor, e, processo de tratamento de um paciente esquizofrênico

Info

Publication number
BR9508021A
BR9508021A BR9508021-0A BR9508021A BR9508021A BR 9508021 A BR9508021 A BR 9508021A BR 9508021 A BR9508021 A BR 9508021A BR 9508021 A BR9508021 A BR 9508021A
Authority
BR
Brazil
Prior art keywords
schizophrenic
treatment
pharmaceutical composition
immunosuppressive agent
pct
Prior art date
Application number
BR9508021-0A
Other languages
English (en)
Inventor
Meir Shinitzky
Michael Deckmann
Original Assignee
Yeda Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Res & Dev filed Critical Yeda Res & Dev
Publication of BR9508021A publication Critical patent/BR9508021A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"COMPOSIçãO FARMACêUTICA PARA O TRATAMENTO DE DISTúRBIOS ESQUIZOFRêNICOS, USO DE UM AGENTE IMUNOSSUPRESSOR, E, PROCESSO DE TRATAMENTO DE UM PACIENTE ESQUIZOFRêNICO". A presente invenção refere-se a uma composição farmacêutica para o tratamento de distúrbios esquizofrênicos a qual compreende um veículo farmaceuticamente aceitável e um agente imunossupressor como ingrediente ativo.
BR9508021-0A 1994-06-13 1995-06-13 Composição farmacêutica para o tratamento de distúrbios esquizofrênicos, uso de um agente imunossupressor, e, processo de tratamento de um paciente esquizofrênico BR9508021A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IL11001194A IL110011A (en) 1994-06-13 1994-06-13 Pharmacological preparations for the treatment of schizophrenia
PCT/EP1995/002289 WO1995034306A1 (en) 1994-06-13 1995-06-13 Use of immunosuppressive agents for the treatment of schizophrenia

Publications (1)

Publication Number Publication Date
BR9508021A true BR9508021A (pt) 2004-04-20

Family

ID=11066236

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9508021-0A BR9508021A (pt) 1994-06-13 1995-06-13 Composição farmacêutica para o tratamento de distúrbios esquizofrênicos, uso de um agente imunossupressor, e, processo de tratamento de um paciente esquizofrênico

Country Status (11)

Country Link
US (1) US5912250A (pt)
EP (1) EP0772442B1 (pt)
JP (1) JPH10501257A (pt)
AT (1) ATE216891T1 (pt)
AU (1) AU704355B2 (pt)
BR (1) BR9508021A (pt)
CA (1) CA2192822C (pt)
DE (1) DE69526584T2 (pt)
ES (1) ES2176331T3 (pt)
IL (1) IL110011A (pt)
WO (1) WO1995034306A1 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6013621A (en) * 1997-10-17 2000-01-11 The Rockfeller University Method of treating psychosis and/or hyperactivity
AU1103699A (en) * 1997-10-17 1999-05-10 Rockefeller University, The Use of an inhibitor of the dephosphorylation of darpp-32 for treating schizophrenia
US6204245B1 (en) * 1999-09-17 2001-03-20 The Regents Of The University Of California Treatment of narcolepsy with immunosuppressants
US7112566B1 (en) * 1999-09-17 2006-09-26 The Regents Of The University Of California Systemic administration of Hypocretin-1
DE60327634D1 (de) 2002-08-22 2009-06-25 Dainippon Sumitomo Pharma Co Mittel zur behandlung des integrationsdysfunktionssyndroms
EP1637530A4 (en) 2003-06-23 2009-04-01 Dainippon Sumitomo Pharma Co THERAPEUTIC AGENT FOR SENILE DEMENTIA
JP4847320B2 (ja) 2004-02-20 2011-12-28 大日本住友製薬株式会社 統合失調症の記憶・学習機能障害治療薬のｉｎｖｉｖｏスクリーニング方法
WO2008008472A2 (en) * 2006-07-13 2008-01-17 President And Fellows Of Harvard College Methods and compositions for modulating synapse formation
US8258139B2 (en) 2010-11-08 2012-09-04 Dainippon Sumitomo Pharma Co., Ltd. Method of treatment for mental disorders

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9203814D0 (en) * 1992-02-21 1992-04-08 Univ London Treatment of long term auto-immune conditions

Also Published As

Publication number Publication date
WO1995034306A1 (en) 1995-12-21
EP0772442A1 (en) 1997-05-14
DE69526584D1 (de) 2002-06-06
JPH10501257A (ja) 1998-02-03
CA2192822C (en) 2007-04-03
AU704355B2 (en) 1999-04-22
US5912250A (en) 1999-06-15
ES2176331T3 (es) 2002-12-01
IL110011A (en) 2004-09-27
AU2881995A (en) 1996-01-05
IL110011A0 (en) 1994-10-07
DE69526584T2 (de) 2002-11-14
EP0772442B1 (en) 2002-05-02
CA2192822A1 (en) 1995-12-21
ATE216891T1 (de) 2002-05-15

Similar Documents

Publication Publication Date Title
ES2167377T3 (es) Derivados de piridina farmacologicamente activos y procedimientos para la preparacion de los mismos.
FI956014A0 (fi) Nona- ja dekapeptidien käyttö lääkkeen valmistamiseksi AIDS-sairauden hoitoon
DE59511002D1 (de) Wirkstoffe für die behandlung der senilen xerosis und zubereitungen
PT760649E (pt) Formulacoes a base de propionato de fluticasona
DE69518334T2 (de) Pharmazeutische aerosol welche mindestens ein zucker enthält
CZ176595A3 (en) The application of anticonvulsive agents for the preparation of medicaments intended for treating parkinson's disease and parkinson's syndromes
BR9908510A (pt) Uso de um composto, composto, processo para a preparação de um composto, composição farmacêutica, e, processo de tratar um paciente que sofre de, ou em risco de, uma doença micobacteriana
TW324662B (en) Benzamide-containing pharmaceutical composition
WO1997004788A3 (en) Use of calendula glycosides for the treatment of psoriasis
BR9508021A (pt) Composição farmacêutica para o tratamento de distúrbios esquizofrênicos, uso de um agente imunossupressor, e, processo de tratamento de um paciente esquizofrênico
MX9403088A (es) Composiciones farmaceuticas que contienen deriva- dos de indol y metodos de uso.
FI962550A0 (fi) Deuterisoidut vaikuttavat aineet transdermaalisessa käyttötarkoituksessa
BR9506748A (pt) Compostos preparação farmacêutica utilização de um composto e processos para o tratamento de um indivíduo sofrendo de dor e para a preparação de um composto
RU94041028A (ru) Применение производных мелатонина для лечения десинхронизационных нарушений, фармацевтическая композиция
BR9611276A (pt) Composto formulação farmacêutica processo para tratamento ou profilaxia de doenças ou condições de seres humanos e uso de um composto
BR9406865A (pt) Uso de um sal farmaceuticamente aceitável de ropivacaina na fabricaçao de um produto farmaceutico processo para o tratamento de uma pessoa necessitando de alivio da dor e preparaçao farmaceutica
AU4091597A (en) Sulfonyl fluorides for the treatment of alzheimer's disease
PT742716E (pt) Composicao farmaceutica para administracao transdermica sistemica contendo a substancia activa morfina-6-glucuronido
ES2157984T3 (es) Utilizacion de 4'-yodo-4'-desoxidoxorrubicina para el tratamiento de la amidoidosis.
BR9908838A (pt) Uso de um glicocorticóide, processeo para tratar glomerulonefrite aguda ou crÈnica, e, composição farmacêutica para tratar glomerulonefrite
BR9713044A (pt) Composto, uso de um composto, processo para sua preparação,e, formulação farmacêutica.
BR9710629A (pt) Composi-Æo farmac-utica processo para sua prepara-Æo composto para utiliza-Æo como agente terap-utico e utiliza-Æo e utiliza-Æo de um composto
MX9302986A (es) Medicamento que contiene metrifonato y procedimiento para su preparacion
WO1994016705A3 (en) Pharmaceutical composition containing 5-morpholinomethyl-3-(4-chlorobenzylideneamine)-2-oxazolidinone and its use for the treatment of cns disorders
ES2146683T3 (es) Uso de bifemelano para la fabricacion de un medicamento para el tratamiento de trastornos hipercineticos.

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]